Xilio Therapeutics, Inc. (XLO)

Market Cap	49.32M +32.8%
Revenue (ttm)	43.77M +589.9%
Net Income	-35.04M
EPS	-4.19
Shares Out	5.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,794
Open	8.27
Previous Close	8.37
Day's Range	8.27 - 8.63
52-Week Range	6.47 - 16.52
Beta	-0.02
Analysts	Buy
Price Target	28.00 (+228.25%)
Earnings Date	Mar 23, 2026

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineere...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 22, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: XLO
• Website: https://xiliotx.com

Financial Performance

In 2025, Xilio Therapeutics's revenue was $43.77 million, an increase of 589.88% compared to the previous year's $6.34 million. Losses were -$35.04 million, -39.84% less than in 2024.

Analyst Summary

According to one analyst, the rating for XLO stock is "Buy" and the 12-month stock price target is $28.0.

Price Target

$28.0

(228.25% upside)

Analyst Consensus: Buy